CD4 and neoplasm: In vivo experiments show that PTSK@CRM possesses a favorable tumor-targeting ability to effectively suppress tumor growth and increase the infiltration of immune cells, including CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, M1-like macrophages, and mature dendritic cells.